<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00393276</url>
  </required_header>
  <id_info>
    <org_study_id>A5232</org_study_id>
    <secondary_id>10154</secondary_id>
    <secondary_id>1R21AI066957-01</secondary_id>
    <secondary_id>ACTG A5232</secondary_id>
    <nct_id>NCT00393276</nct_id>
  </id_info>
  <brief_title>Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals</brief_title>
  <official_title>Optimizing Vaccine Responsiveness in HIV-1 and HCV Infections by Identifying Determinants of Responsiveness: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      Infection with either HIV or hepatitis C virus (HCV) affects immune system responses. The&#xD;
      purpose of this study is to investigate the immune responses to two different vaccine&#xD;
      formulations in HIV-infected, HCV-infected, and HCV/HIV- coinfected individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with HCV and HIV coinfection are especially hard to treat, and as a result,&#xD;
      account for a high rate of deaths each year. Because HCV and HIV share transmission routes,&#xD;
      HCV/HIV coinfection is common. Liver disease has emerged as a significant cause of death in&#xD;
      individuals coinfected with HCV and HIV. Currently, the mechanisms by which HCV and HIV&#xD;
      interact in HCV/HIV-coinfected individuals, including how these infections affect immune&#xD;
      responses, are poorly understood. Research suggests that vaccination may prevent other&#xD;
      comorbidities associated with HCV/HIV coinfection; however, responses to new vaccine antigens&#xD;
      have been shown to be impaired in HCV or HIV-infected individuals. The purpose of this study&#xD;
      is to identify the innate and adaptive immune defects present in HCV-infected, HIV-infected,&#xD;
      and HCV/HIV-coinfected individuals. This study will evaluate whether these innate and&#xD;
      adaptive immune defects predict responses to HBV neoantigen in the form of both a&#xD;
      diphtheria/tetanus toxoid immunization (Decavac)and a hepatitis A-hepatitis B immunization&#xD;
      (Twinrix).&#xD;
&#xD;
      This study will last approximately 24 weeks. Participants will be stratified to one of three&#xD;
      arms, based on their HCV and HIV status:&#xD;
&#xD;
        -  Arm A will enroll HCV-infected individuals who are HIV-uninfected&#xD;
&#xD;
        -  Arm B will enroll HIV-infected individuals who are HCV-uninfected&#xD;
&#xD;
        -  Arm C will enroll HCV/HIV-coinfected individuals&#xD;
&#xD;
      Arms B and C will open for enrollment before Arm A. Opening of enrollment for Arm A will be&#xD;
      determined by the accrual progress of Arms B and C as evaluated by the ACTG Scientific Agenda&#xD;
      Steering committee.&#xD;
&#xD;
      All participants will receive Decavac vaccination on Day 0, and a Twinrix vaccination on Days&#xD;
      0, 7, and 21. Study visits will occur around Days 0, 7, and 21, and at Weeks 6, 8, 12, and&#xD;
      24; all visits will include medical and medication history, blood collection, and a physical&#xD;
      exam. Medication to treat HCV or HIV will not be provided by the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>B-cell humoral responses</measure>
    <time_frame>At Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T-cell responses as reflected by hepatitis B and tetanus antibody titers</measure>
    <time_frame>At Week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dendritic cell, B-cell, and T-cell functional markers</measure>
    <time_frame>At Study Entry</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>B-cell functional marker</measure>
    <time_frame>At Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell responses to hepatitis A, hepatitis B, and tetanus antigens</measure>
    <time_frame>At Weeks 3 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal serum antibody titers to hepatitis A, hepatitis B, and tetanus (B-cell responses)</measure>
    <time_frame>At Study Entry and Weeks 1, 3, 6, 8, 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4/CD8 and HCV genotype</measure>
    <time_frame>At Study entry</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline antibody status for hepatitis B core antigen (anti-HBc)</measure>
    <time_frame>At Study entry</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV-infected defined as a positive result using polymerase chain reaction (PCR) without previous HCV-based therapy and without the presence of Child's B or C cirrhosis. These participants will be HIV-uninfected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-infected and ARV naive, with a CD4 cell count of 300 cells/mm3 or greater, with no prior or current opportunistic infection, and with no indication for HIV therapy. These participants will be HCV-uninfected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV/HIV-coinfected as defined above in Arms A and B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Twinrix</intervention_name>
    <description>Combined hepatitis A and hepatitis B immunization</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Decavac</intervention_name>
    <description>Diphtheria and tetanus toxoid vaccine</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Arm A Participants:&#xD;
&#xD;
          -  HCV-infected&#xD;
&#xD;
          -  HIV-uninfected&#xD;
&#xD;
        Inclusion Criteria for Arm B Participants:&#xD;
&#xD;
          -  HIV-infected&#xD;
&#xD;
          -  HCV-uninfected&#xD;
&#xD;
          -  CD4 count greater than or equal to 300 cells/mm3 within 60 days prior to study entry&#xD;
&#xD;
        Inclusion Criteria for Arm C Participants:&#xD;
&#xD;
          -  HIV-infected&#xD;
&#xD;
          -  HCV-infected&#xD;
&#xD;
        Inclusion Criteria for All Participants:&#xD;
&#xD;
          -  Documented hepatitis B virus (HBV) antibody status. If anti-HBV core antibody&#xD;
             positive, documented HBV negative test within 30 days prior to study entry is&#xD;
             required.&#xD;
&#xD;
          -  Willing to use acceptable forms of contraception for the duration of the study and for&#xD;
             24 weeks after the last vaccination&#xD;
&#xD;
        Exclusion Criteria for Arm A Participants:&#xD;
&#xD;
          -  Concurrent or recent treatment for HCV infection (within the past three months)&#xD;
&#xD;
        Exclusion Criteria for Arm B Participants:&#xD;
&#xD;
          -  Current, prior, or clinical need for antiretroviral therapy (within the past three&#xD;
             months prior to study entry)&#xD;
&#xD;
          -  Opportunistic infection other than HCV&#xD;
&#xD;
        Exclusion Criteria for Arm C Participants:&#xD;
&#xD;
          -  Concurrent or recent treatment for HCV infection (within the past three months)&#xD;
&#xD;
          -  Current, prior, or clinical need for antiretroviral therapy (within the past three&#xD;
             months prior to study entry). More information on this criterion can be found in the&#xD;
             protocol.&#xD;
&#xD;
          -  Opportunistic infection other than HCV&#xD;
&#xD;
        Exclusion Criteria for All Participants:&#xD;
&#xD;
          -  History of exposure to hepatitis A vaccine, hepatitis B vaccine, or combined hepatitis&#xD;
             A-hepatitis B vaccines&#xD;
&#xD;
          -  Immunomodulatory agents for 7 days or more within 30 days prior to study entry. More&#xD;
             information on this criterion can be found in the protocol.&#xD;
&#xD;
          -  Concurrent immunizations (e.g., influenza, pneumococcal, other vaccine)within 3 days&#xD;
             prior to study entry&#xD;
&#xD;
          -  Active or recent (in the last six months prior to study entry) CDC Category C event.&#xD;
             More information on this criterion can be found in the protocol&#xD;
&#xD;
          -  Systemic anticancer chemotherapy or radiation within 24 weeks prior to study entry, or&#xD;
             anticipated need to begin such treatment&#xD;
&#xD;
          -  Past or current immunologically-mediated disease. More information on this criterion&#xD;
             can be found in the protocol.&#xD;
&#xD;
          -  Current bacterial infection requiring treatment, therapy, or hospitalization within 1&#xD;
             week prior to study entry&#xD;
&#xD;
          -  Serious illness requiring systemic treatment and/or hospitalization. Participants who&#xD;
             complete therapy or are clinically stable on therapy for at least 14 days prior to&#xD;
             study entry are not excluded.&#xD;
&#xD;
          -  Current uncontrolled seizure disorders&#xD;
&#xD;
          -  Active bleeding varices, or Child's B or C cirrhosis. More information on this&#xD;
             criterion can be found in the protocol.&#xD;
&#xD;
          -  Serious bleeding disorder that poses a risk to a participant for intramuscular&#xD;
             injections&#xD;
&#xD;
          -  Known allergy or sensitivity to study vaccines or their formulations&#xD;
&#xD;
          -  Current drug or alcohol use that, in the opinion of the investigator, interferes with&#xD;
             study participation&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Use of systemic investigational agents within 30 days prior to entry&#xD;
&#xD;
          -  History of any hepatitis A vaccine within one year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald D. Anthony, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benigno Rodriguez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Infectious Diseases, University Hospital of Cleveland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center CRS</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsf Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHV Baltimore Treatment CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Clinical Research Site (MGH CRS) CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia P&amp;S CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ. Med. Ctr. Adult CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Health and Wellness Center CRS</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico AIDS Clinical Trials Unit CRS</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1605</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/Recommended_Immunizations_FS_en.pdf</url>
    <description>Click here for more information on recommended immunizations for HIV positive adults</description>
  </link>
  <reference>
    <citation>Maier I, Wu GY. Hepatitis C and HIV co-infection: a review. World J Gastroenterol. 2002 Aug;8(4):577-9. Review.</citation>
    <PMID>12174359</PMID>
  </reference>
  <reference>
    <citation>Rockstroh JK. Management of hepatitis B and C in HIV co-infected patients. J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S59-65. Review.</citation>
    <PMID>14562859</PMID>
  </reference>
  <reference>
    <citation>Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000 Apr;30 Suppl 1:S77-84. Review.</citation>
    <PMID>10770916</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2006</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment Experienced</keyword>
  <keyword>Treatment Naive</keyword>
  <keyword>Immunizations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

